Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irina Proskorovsky

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Advances in Therapy|May 30, 2019
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic LeukemiaIrina Proskorovsky, Yun Su, Kyle Fahrbach, et al.
Current Medical Research and Opinion|October 6, 2018
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancerKaren Reckamp, Huamao M Lin, Joice Huang, et al.
BMC Cancer|December 21, 2018
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analysesIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, et al.
Transfusion|September 21, 2007
Clinical and economic burden of infused iron chelation therapy in the United StatesKrista A Payne, Marie-Pierre Desrosiers, J Jaime Caro, et al.
Advances in Therapy|September 8, 2025
An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe DiseaseMark E Roberts, Irina Proskorovsky, Patricia Guyot, et al.
Advances in Therapy|August 16, 2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overloadKrista A Payne, Diana Rofail, Jean-François Baladi, et al.
Molecular Genetics and Metabolism Reports|July 22, 2024
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trialsTahseen Mozaffar, Lionel Riou França, Jérôme Msihid, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 15, 2013
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort studyKarin Jordan, Irina Proskorovsky, Philip Lewis, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|September 7, 2007
Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical careJack Ansell, J Jaime Caro, Maribel Salas, et al.
Clinical Lung Cancer|December 19, 2023
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment ComparisonSai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Advances in Therapy|May 30, 2019
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic LeukemiaIrina Proskorovsky, Yun Su, Kyle Fahrbach, et al.
Current Medical Research and Opinion|October 6, 2018
Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancerKaren Reckamp, Huamao M Lin, Joice Huang, et al.
BMC Cancer|December 21, 2018
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analysesIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, et al.
Transfusion|September 21, 2007
Clinical and economic burden of infused iron chelation therapy in the United StatesKrista A Payne, Marie-Pierre Desrosiers, J Jaime Caro, et al.
Advances in Therapy|September 8, 2025
An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe DiseaseMark E Roberts, Irina Proskorovsky, Patricia Guyot, et al.
Advances in Therapy|August 16, 2008
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overloadKrista A Payne, Diana Rofail, Jean-François Baladi, et al.
Molecular Genetics and Metabolism Reports|July 22, 2024
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trialsTahseen Mozaffar, Lionel Riou França, Jérôme Msihid, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 15, 2013
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort studyKarin Jordan, Irina Proskorovsky, Philip Lewis, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|September 7, 2007
Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical careJack Ansell, J Jaime Caro, Maribel Salas, et al.
Clinical Lung Cancer|December 19, 2023
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment ComparisonSai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, et al.
Pageof 4